AmbioPharm, Inc.

Your American Peptides Partner with Global Reach



A Trusted CDMO in Peptides Delivering for Your Patients

With deep peptide expertise and a shared commitment to improving patients' lives, we work side by side with you and your team to move therapies forward from early development through launch and into commercial supply. Our flexible, collaborative approach means we listen closely, adapt to your needs, and stay aligned with your goals, forming a lasting relationship that deliver patient-centric therapies.

This firm foundation is grounded in our three-pronged approach that advances and modernizes therapies that make a real difference in people's lives.

Peptides

Innovation starts with deep scientific collaboration, unlocking new therapeutic potential.

Process

Precision, partnership, and proven expertise drive every stage, ensuring quality, scalability, and regulatory excellence from lab to launch.

Patient

Every decision, every detail, and every molecule is designed with one purpose: to improve patients' lives through safer, more effective therapies.

Our Differentiators. Your Competitive Advantage.

- Leaders in Hybrid Synthesis
- Dedicated Project Managers
- Process Development
- Analytical Development (AMD)
- US country of origin

Our team listens closely and evolves with you, ensuring seamless collaboration from start to finish.

Upstream Synthesis

Our upstream synthesis capabilities span SPPS, LPPS and Hybrid approaches, each tailored for scalability and complexity.

	SPPS	Hybrid Synthesis	LPPS
Capacity	Up to 3,000L Lines	Up to 5,000L Lines	Up to 5,000L Lines
API Batch Size	>20kg	>100kg	>500kg
Advantages	• Fast development time • Cost-effective for medium length peptides	• Complex peptides • Cost-effective for longer peptides • Highly scalable	• Cost-effective for shorter peptides • May avoid HPLC purification • Highly scalable

Downstream Processing

Downstream processing is optimized for purity, efficiency and scale.

	HPLC Purification	Lyophilization	Centrifuges	Precipitation/ Crystallization
Capacity	Up to 1M columns	Up to 1,000L	Up to 500L	Up to 1,500L

AmbioPharm Facilities

	North Augusta Campus	Shanghai Campus
SPPS	⬢	⬢
LPPS	⬢	⬢
Hybrid Synthesis	⬢	⬢
Process Development	⬢	⬢
Optimization & Scale Up	⬢	⬢
Downstream Processing	⬢	⬢
Tangential Flow Filtration	⬢	⬢
Quality Control	⬢	⬢
Analytical Services	⬢	⬢

⬢ = Current Capabilities ⬢ = Future Capabilities

With project managers positioned across key global regions, you can count on responsive support wherever you are.

Our Capabilities. Your Innovation for Patients.

Clinical Peptide Synthesis

- GMP and non-GMP manufacturing
- Solid-phase, liquid-phase, and hybrid synthesis
- Fragment-based and complex peptides

Process Development & Scale-up

- Early phase development and support
- Seamless tech transfer between sites
- Optimization for yield, purity and scalability

Analytical & Quality Support

- Method development and validation
- In-process and release testing

Regulatory & Documentation Support

- CMC documents
- Support IND, NDA and global filings

Dual Manufacturing

- US and Shanghai facilities with mirrored equipment (once North Augusta expansion is complete) supporting global scalability

Sustainability & Green Chemistry

- Commitment to environmentally responsible practices
- **40%** reduction in amino acid consumption compared to SPPS
- Lower solvent usage (reduced by **30%** and allowing the use of greener solvents)
- Higher crude purity (increased by **10%**)



Global CDMO Proven Expertise

AmbioPharm.com

AmbioPharm, Inc.